May Tan, PhD

Nurix Therapeutics, Inc.

N/A

Poster(s):

• 1312 - Zelebrudomide (NX-2127) is a cereblon-modulating BTK degrader that reverses immune dysfunction and modifies both T-cell and CLL-cell transcriptional signatures in patients with CLL